Major Depressive Episode
0
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Mission TherapeuticsUK - Cambridge
2 programsKetaminePHASE_21 trial
KetaminePHASE_41 trial
Active Trials
Cognition TherapeuticsPA - Pittsburgh
1 programPen and Paper Digit Symbol Substitution TestN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Mission TherapeuticsKetamine
Mission TherapeuticsKetamine
Cognition TherapeuticsPen and Paper Digit Symbol Substitution Test
Clinical Trials (3)
Total enrollment: 155 patients across 3 trials
Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)
Start: Apr 2008Est. completion: Oct 201283 patients
Phase 4Completed
A Study of Ketamine as an Antidepressant
Start: Sep 2011Est. completion: Dec 201442 patients
Phase 2Unknown
Validation Study: Mobile DSST on Cognition in Adults With MDD
Start: Aug 2019Est. completion: Feb 202030 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.